Liminatus Pharma (LIMN) vs Scinai Immunotherapeutics (SCNI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Liminatus Pharma is the larger company by market cap ($5.1 million vs $1.6 million), about 3.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LIMN | SCNI |
|---|---|---|
| Share price | $3.76 | $1.18 |
| Market cap | $5.05M | $1.60M |
| 1-day change | +1.90% | -2.48% |
| P/E ratio (TTM) | — | 0.04 |
| EPS (TTM) | $-23.88 | $28.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $141.50 | $15.65 |
| 52-week low | $3.29 | $1.06 |
| Distance from 52-week high | -97.34% | -92.46% |
| Average volume | 459.47K | 1.12M |
| Shares outstanding | 1.34M | 1.35M |
| Employees | 1 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Liminatus Pharma is about 3.2 times larger than Scinai Immunotherapeutics by market value ($5.05M vs $1.60M).
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
LIMN vs SCNI FAQ
Which is bigger, Liminatus Pharma or Scinai Immunotherapeutics?
Liminatus Pharma (LIMN) is larger, with a market capitalization of $5.05M compared with $1.60M for Scinai Immunotherapeutics (SCNI).
Are Liminatus Pharma and Scinai Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.